Journal
LEUKEMIA & LYMPHOMA
Volume 45, Issue 2, Pages 401-403Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190310001593184
Keywords
ALL; CML; imatinib; CNS relapse
Categories
Ask authors/readers for more resources
Philadelphia chromosome positive ALL and CML have shown remarkable responses to imatinib (Gleevec, STI571) in phase I, II and III studies. However, imatinib has very poor penetration of the blood brain barrier resulting in subtherapeutic levels in the CNS. We present 2 cases of patients treated with imatinib that achieved complete cytogenetic remission within 3 months who subsequently developed CNS relapses while remaining in complete cytogenetic remission on bone marrow examination. Both patients went on to achieve CNS remission following treatment with intrathecal methotrexate and cytarabine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available